Welcome to our dedicated page for Geovax Labs SEC filings (Ticker: GOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeoVax Labs, Inc. (GOVX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, giving investors a structured view of its capital markets activity, governance decisions, and development funding. As a smaller reporting company, GeoVax files registration statements, current reports, and proxy materials that outline its financing transactions, stockholder approvals, and contractual arrangements.
Through registration statements on Form S-1 and Form S-3, GeoVax registers offerings of common stock and warrants, as well as the resale of warrant shares issued in private placements. These filings describe offerings such as registered direct financings and concurrent private placements of common warrants, the number of shares and warrants involved, and intended uses of proceeds, including research and development, manufacturing, clinical studies, capital expenditures, and working capital.
Form 8-K current reports provide details on material events, including the pricing and closing of offerings, entry into placement agency and purchase agreements, government contract developments, and the release of quarterly financial results. 8-K filings also cover special stockholder meetings and the outcomes of votes on proposals such as warrant share issuance approvals and reverse stock split authorizations.
Proxy materials, such as the DEF 14A special meeting proxy statement, outline proposals submitted to stockholders, the rationale for actions like reverse stock splits or warrant exercise approvals, and the mechanics of voting. In addition, Form 25 filings document the removal from listing and/or registration of specific GeoVax securities, such as warrants, from Nasdaq Stock Market LLC.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex documents in plain language. Investors can quickly see the key terms of financing agreements, understand the implications of stockholder votes, and track how government contracts like the BARDA/Project NextGen award are reflected in the company’s disclosures. Real-time updates from EDGAR ensure that new 8-Ks, S-1s, proxy statements, and other filings are available promptly, while dedicated sections for warrant-related disclosures and capital structure changes help users follow the evolution of GOVX’s securities over time.
GeoVax Labs, Inc. (GOVX) reported the results of a special stockholder meeting held on November 26, 2025. Stockholders representing 14,125,083 of the company’s 29,705,360 issued and outstanding common shares as of September 30, 2025, were present by proxy.
Stockholders approved a proposal, required under Nasdaq listing rules, to allow the issuance of up to 11,904,768 shares of common stock upon exercise of common stock purchase warrants that were issued to certain institutional investors in a September 30, 2025 private placement. The proposal received 5,806,374 votes for, 946,094 against, and 870,973 abstentions, with 6,501,642 broker non-votes.
They also approved an amendment to the Certificate of Incorporation to implement a reverse stock split of the issued and outstanding common stock at a ratio between 1-for-10 and 1-for-25, with the exact ratio to be set by the Board of Directors. This proposal received 11,850,760 votes for, 2,158,471 against, and 115,852 abstentions.
GeoVax Labs, Inc. filed a current report to note that it released a press release covering its operating results for the quarter ended September 30, 2025. The company states that this press release, dated November 13, 2025, is furnished as Exhibit 99.1 to the report.
The filing also includes standard forward-looking statement language, explaining that projections and expectations are subject to risks and uncertainties, and that actual results may differ from current views. The report is signed on behalf of GeoVax Labs by its Chief Financial Officer, Mark W. Reynolds.
GeoVax Labs, Inc. is supplementing a prospectus covering the resale of up to 1,605,688 shares of common stock by a selling stockholder, incorporating its latest Quarterly Report on Form 10‑Q for the period ended September 30, 2025.
The company reported no revenue in the third quarter from its government contract after BARDA, through the ATI‑RRPV arrangement, terminated that contract for convenience. Third‑quarter 2025 results show a net loss of $6.3 million, bringing the nine‑month net loss to $17.0 million, similar to the prior year despite lower research and development spending.
GeoVax ended the period with $5.0 million in cash and cash equivalents and 29,705,360 shares outstanding, funded largely by multiple equity offerings and warrant exercises that provided about $16.0 million in net financing cash year‑to‑date. Management states that existing cash is expected to fund operations into December 2025 and that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
GeoVax Labs filed a prospectus supplement covering the resale of up to 2,170,000 shares of common stock by a selling stockholder, updating the prospectus with its Form 10‑Q for the quarter ended September 30, 2025.
In the quarter, the company reported a net loss of
GeoVax Labs, Inc. filed a prospectus supplement updating a resale registration covering up to 1,700,000 shares of common stock by a selling stockholder and incorporating the company’s Q3 2025 Form 10‑Q.
For Q3 2025, GeoVax reported a net loss of
GeoVax completed several financings in 2025, including offerings closed on March 25, July 2, and September 30, and sales through an ATM program. Shares outstanding were 29,705,360 as of November 13, 2025.
GeoVax Labs filed a prospectus supplement for the resale of up to 975,610 shares of common stock by a selling stockholder, updating the base prospectus with its attached Q3 2025 Form 10-Q.
In the quarter, the company reported a net loss of $6,318,914 and $0 revenue, reflecting the previously disclosed termination-for-convenience of the BARDA-related ATI‑RRPV contract. For the nine months, net loss was $17,046,348. Cash and cash equivalents were $5,008,997, and working capital was $4,693,071. The company raised additional capital in March, July, and September 2025 through stock and warrant offerings and sales under its ATM program.
Management states these factors raise substantial doubt about the company’s ability to continue as a going concern. Shares outstanding were 29,705,360 as of November 13, 2025.
GeoVax Labs (GOVX) reported Q3 2025 results marked by a sharp revenue drop and continued losses. Revenue from government contracts was $0 in the quarter versus $2,789,484 a year ago after BARDA-directed work under the ATI‑RRPV contract was terminated for convenience on April 11, 2025. Operating expenses were $6,373,215 and the net loss was $6,318,914, or $0.31 per share.
For the nine months, revenue was $2,489,145, operating expenses totaled $19,686,436, and net loss was $17,046,348 ($0.97 per share). Cash and cash equivalents were $5,008,997, with working capital of $4,693,071. Management states existing cash funds operations into December 2025 and notes “substantial doubt” about the ability to continue as a going concern without additional capital. To support liquidity, the company completed equity financings in March (~$4.1 million net), July (~$5.5 million net), and September (~$2.3 million net), and sold shares via its ATM program (~$4.0 million net for the nine months). As of November 13, 2025, 29,705,360 shares were outstanding.
GeoVax Labs, Inc. filed a Rule 424(b)(3) prospectus covering the resale of up to 11,904,768 shares of common stock, issuable upon exercise of September 2025 warrants issued in a September 30, 2025 private placement. The company will not receive proceeds from sales by the selling stockholders; it would receive cash only if holders exercise the warrants. If exercised for cash in full, gross proceeds would be approximately $7.5 million.
The selling stockholders may sell shares from time to time via market or negotiated transactions as detailed under the plan of distribution. GeoVax’s common stock trades on Nasdaq under GOVX; on October 15, 2025, the last reported sale price was $0.5967 per share. Shares outstanding were 29,705,360 as of October 17, 2025. The company notes a Nasdaq bid-price deficiency letter with a compliance date of January 27, 2026.
GeoVax Labs, Inc. filed a Form S-1 to register the resale of up to 11,904,768 shares of common stock issuable upon exercise of September 2025 warrants issued in a September 30, 2025 private placement. The company states it will not receive proceeds from Selling Stockholder sales; it would receive cash only if warrants are exercised.
If exercised for cash in full, gross proceeds would be approximately $7.5 million, intended for general corporate purposes and working capital. Shares outstanding were 29,705,360 as of October 17, 2025. The prospectus lists additional overhang figures, including 40,027,849 warrants outstanding with a weighted average exercise price of $0.70 per share, and option reserves under stock plans.
The filing notes the Nasdaq listing under “GOVX” and discloses a Nasdaq bid price deficiency with an initial compliance period through January 27, 2026.
GeoVax Labs (GOVX) called a Special Meeting on November 26, 2025 to seek stockholder approval for two actions. First, the company requests authorization to issue up to 11,904,768 shares of common stock upon exercise of its September 2025 Warrants at an exercise price of $0.63 per share, which expire five years after stockholder approval. These warrants include a 4.99% ownership blocker (increasable to 9.99% with notice) and price-adjustment features consistent with Nasdaq rules. If exercised in full, GeoVax notes potential gross proceeds of approximately $7,500,000.
Second, the Board seeks discretionary authority to implement a reverse stock split in a ratio between 1-for-10 and 1-for-25 to help regain compliance with Nasdaq’s $1.00 minimum bid requirement after a notice received on July 31, 2025, with the compliance period running to January 27, 2026. There were 29,705,360 shares outstanding as of September 30, 2025. The Board recommends voting FOR both proposals.